Aphios Pharma, with a valuation of $68.9 million, is raising funds on NetCapital. The company is developing cannabis-based therapeutics for pain, anxiety, opioid use disorder, and multiple sclerosis. Aphios Pharma is developing technology for the sustained release of nano-encapsulated cannabinoids for chronic medical needs. The green biotech company has received grants from the National Cancer Institute, NCCIH, and National Institute of Drug Abuse and has spent millions of dollars on drug manufacturing and drug delivery technologies. Dr. Trevor P. Castor founded Aphios Pharma in July 2018. The current crowdfunding campaign has a minimum target of $10,000.08 and a maximum target of $617,999.44. The campaign proceeds will be used for pre-clinical studies, marketing, rent and occupancy, legal and accounting fees, repair and maintenance, R&D, and G&A expenses.
Investment Overview
Raised: $17,135
Deal Terms
Total Commitments ($USD)
- Platform
- Netcapital
- Start Date
- 10/14/2024
- Close Date
- 01/17/2025
$10,000
$617,999
$100
Equity - Common
Pre-Seed
RegCF
$3.44
$68,959,967
Company & Team
Company
- Year Founded
- 2018
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $0
- VC Backed?
- No
Growth Charts
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Valuation History
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.